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REFERENCES 18Abstract. We consider the problem of assessing new and existing technologies for their
cost-eﬀectiveness in the case where data on both costs and eﬀects are available from a
clinical trial, and we address it by means of the cost-eﬀectiveness acceptability curve. The
main diﬃculty in these analyses is that cost data usually exhibit highly skew and heavy-
tailed distributions, so that it can be extremely diﬃcult to produce realistic probabilistic
models for the underlying population distribution, and in particular to model accurately the
tail of the distribution, which is highly inﬂuential in estimating the population mean. Here,
in order to integrate the uncertainty about the model into the analysis of cost data and into
cost-eﬀectiveness analyses, we consider an approach based on Bayesian model averaging:
instead of choosing a single parametric model, we specify a set of plausible models for
costs and estimate the mean cost with its posterior expectation, that can be obtained as
a weighted mean of the posterior expectations under each model, with weights given by
the posterior model probabilities. The results are compared with those obtained with a
semi-parametric approach that does not require any assumption about the distribution of
costs.
1 Introduction
The increasing burden on the budgets of health care providers has resulted in con-
siderable interest in assessing new and existing technologies for their clinical eﬀec-
tiveness and cost-eﬀectiveness.
Suppose that two health care technologies T1 and T2 are to be compared in a




T : i = 1;2; j = 1;2;:::;ni
o
where eij and cij are the eﬀect and the cost of treatment i on patient j respectively.
In order to assess if T2 is more cost-eﬀective than T1, we need to compare expected
eﬀects °i and expected costs ¹i for each treatment. Let ∆e = °2¡°1 and ∆c = ¹2¡¹1
be the eﬀect and cost diﬀerentials. Moreover, let K be a decision-maker’s willingness
to pay coeﬃcient, that is the units of money a decision maker is prepared to pay to
obtain one unit of eﬀectiveness.
The primary measure of cost-eﬀectiveness of T2 relative to T1 is usually consid-
ered to be the incremental cost-eﬀectiveness ratio, deﬁned as ½ = ∆c=∆e. However,
as pointed out for instance in O’Hagan et al. (2000), cost-eﬀectiveness of T2 does
not simply equate to ½ being less than K. It also depends on the sign of ∆e, so
1that it is the sign of the net monetary beneﬁt K∆e ¡ ∆c that is of interest: T2 is
cost-eﬀective relative to T1 if K∆e ¡ ∆c > 0, i:e: if in the plane of possible pairs
of values of the population mean increments of eﬀect and cost, (∆e;∆c) is below
a sloping line of gradient K. This is usually referred as the Net Beneﬁt approach
(Stinnett and Mullahy, 1998), and inference about the net monetary beneﬁt is gen-
erally presented by means of a Cost-Eﬀectiveness Acceptability Curve (CEAC), that
plots the probability Q(K) that the net beneﬁt is positive against the coeﬃcient
K (van Hout et al., 1994), which is rarely unambiguously determined in practice.
In this sense, a Bayesian approach is particularly natural, since no such probability
exists or has any meaning in frequentist statistics (O’Hagan et al., 2000). Thus, in
the rest of the paper we assume that Q(K) is the posterior probability
Q(K) = P (K∆e ¡ ∆c > 0 jD):
Clearly these cost-eﬀectiveness analyses of clinical trial data rely on statistical
models which describe the distribution of costs and eﬀects and their interrelation
across individual in the trial. The choice of models used in practice is often deter-
mined by convenience, and in particular it is often assumed that the data on costs
and eﬀects follow a bivariate normal distribution in each arm of the trial. How-
ever, although such assumption may be convenient for computational purposes, it
is rarely realistic. In particular, cost data obtained for individual patients in health
economic studies typically exhibit highly skew and heavy tailed distributions, and
many problems arise with the various approaches currently available for analysing
such data.
In fact, as discussed in O’Hagan and Stevens (2002, 2003), non-parametric meth-
ods, such as those based on the asymptotic normality of the sample mean or nonpara-
metric bootstrapping, may be ineﬃcient and their justiﬁcation breaks down in small
samples. See Dinh and Zhou (2006) for some recent developments on such methods.
On the other hand, parametric modelling may lead to more eﬃcient inference, but
is dependent on the population distribution matching the model adequately. The
main diﬃculty in this sense, as pointed out for instance in Nixon and Thompson
(2004) and Thompson and Nixon (2005), is that the high skewness and kurtosis
usually found in cost data imply that the population mean can be very sensitive to
the tail of the distribution, that it is quite complicated to model accurately. One
consequence of this is that parametric models that ﬁt the data equally well can pro-
duce very diﬀerent answers; conversely, in some cases models that ﬁt badly can give
2similar inferences to those that ﬁt well. For these reasons, Thompson and Nixon
(2005) recommend that the sensitivity of conclusions to the choice of the model is
always investigated, so that model uncertainty becomes a crucial aspect of analysing
cost data. They also suggest that, instead than allowing an arbitrary long tail for
cost distributions, it might be more plausible to consider truncated distributions (for
instance at twice the maximum observed cost), because costs for individual patients
are bound to have some ﬁnite limit in practice. It is also interesting to note the pa-
per by Briggs et al. (2005), where it is shown that (frequentist) inferences based on
incorrect parametric assumptions, and in particular on the assumption of lognormal-
ity when the data come from a diﬀerent distribution, can lead to totally misleading
conclusions. Another problem related to the parametric modelling of costs concerns
possible transformations of the data; in fact, as discussed in Thompson and Bar-
ber (2000) and Briggs and Gray (1998), mean values and conﬁdence limits may be
diﬃcult to interpret on the transformed scales, and back-transformation onto the
original scale is not always straightforward.
Here, in order to integrate the uncertainty about the model into the analysis
of cost data and into cost-eﬀectiveness analyses, we consider an approach based on
Bayesian model averaging. This is presented in details in Section 2, and is compared
with the semi-parametric approach of Conigliani and Tancredi (2005a, 2005b), that
was introduced with the same aim of reporting model-based inference for mean
costs without having to be too concerned about model misspeciﬁcation problems.
In Section 3 we consider the relative performance of the two approaches simulating
cost data from a number of assumed parametric distributions. In Section 4 we
repeat the comparison in an empirical context using a study on low back pain. A
few concluding remarks are presented in the ﬁnal section.
2 The model
In order to focus the attention on the distribution of costs, we ﬁnd convenient to
write the distribution for a single observation xij under treatment Ti as:
gi (xij jµi;Ái) = fi (cij jµi)hi (eij jcij;Ái)
where fi (cij jµi) is the unconditional distribution for the cost of patient j under
treatment Ti and hi (eij jcij;Ái) is the conditional distribution for the eﬀect on pa-
tient j under treatment Ti given the cost cij. In the remaining of this section we
3will focus on the problem of specifying fi (cij jµi); the choice of hi (eij jcij;Ái) usually
does not present too many problems, and will be addressed only in the example.
2.1 Bayesian model averaging
Suppose that under both treatment groups, instead of choosing a single paramet-
ric model for a cost observation cij, we specify a set of plausible models M =
fm = 1;2;:::;Mg. Also assume that the mean cost ¹i is an unknown parameter of
all models in M, and that aim of the analysis is obtaining the marginal posterior
mean of ¹i. This is exactly a setting where Bayesian model averaging (BMA) can be
applied to obtain the desired summary (Hoeting et al. 1999). In fact, the posterior
marginal distribution of ¹i can be obtained as a mixture of its posterior marginal





and the posterior expectation of ¹i can be expressed as a weighted mean of its





with the mixing probabilities given by the posterior model probabilities ¼(mjci1;:::;cini).
2.1.1 Prior assumptions and computational issues
Here we assume that the set M is made of the log-normal, the gamma, the Weibull,
the log-logistic and the generalised Pareto distribution (GPD), not all necessarily
having non-zero prior model probabilities; the probability density function, the mean
and the coeﬃcient of variation of these distributions are shown in Table 1. Moreover,
we assume that the ﬁve distributions have ﬁnite mean and variance, so that for the
GPD and the log-logistic we need to constrain the shape parameter to be less than
0.5. Then all models can be re-parametrized in terms of the mean cost ¹i and the
coeﬃcient of variation ¿i, and this is particularly useful when specifying the prior
distributions for the parameters of the diﬀerent models. In fact, it implies that the
same prior distribution can be introduced under the various models in M, and that










































































(½ < 1) (½ < 1=2)
the unknown parameters have a clear meaning, so that it is not diﬃcult to elicit
such prior from the experts’ opinions. In particular, we assume that
¼i (¹i;¿i) = ¼i (¹i j¿i)¼i (¿i)
where




















i are known constants.
Finally note that Bayesian inference for this model is possible using Markov chain
Monte Carlo (MCMC) methods (see, for instance, Robert and Casella, 1999). In
particular, one can simulate from the posterior distributions of the parameters under
each of the models in M, and then compute the marginal likelihoods required for
obtaining the posterior model probabilities for instance with the method of Chib and
Jeliazkov (2001). Alternatively, it is usually more eﬃcient to use a single Markov
Chain with Metropolis Hastings moves to explore both the parametric space within
each model and to switch among models (see, for instance, O’Hagan and Forster,
2004, Chapter 10). Note that when all the models in M have the same number
5of parameters, there is no need to apply the reversible jump methodology (Green,
2000), which anyway can be easily implemented to handle more general situations.
2.2 A semi-parametric approach
In recognising the extreme complexity of cost distributions (the construction of cost
data as a weighted sum of diﬀerent resource counts implies that cost distributions
are really mixtures of many diﬀerent distributions), Conigliani and Tancredi (2005a)
suggested to model the bulk of the data and the tails separately. More speciﬁcally,
for the problem of estimating the population mean cost diﬀerential, they introduce
a distribution composed of a piecewise constant density up to an unknown endpoint,
and a generalised Pareto distribution for the remaining tail data. The ﬁrst compo-
nent of the model, the step function, is very ﬂexible, in the sense that it has the
appealing property of catching all the relevant features of the data; if for instance
the data exhibit multimodality, the corresponding model will be multimodal. How-
ever, the step function will hardly give any weight to values beyond the range of
the data; for this reason, they introduced a diﬀerent model for the upper tail of
the distribution, the GPD, that is often used in extreme value theory to model tail
data (Coles, 2001). Note this model has been applied to environmental data by
Tancredi et al. (2002), and to cost-eﬀectiveness analyses in the simple case where
eﬀects are measured as binary outcomes by Conigliani and Tancredi (2005b). Thus,
for purposes of comparison with the approach of Section 2.1, here we assume this


















® · cij < 1
(1)
where ! is the probability that an observation cij is greater than ®, s is the (un-
known) number of steps of the piecewise constant density, a(s) = (a2;:::;as) and
!(s) = (!1;:::;!s) denote the vector of (unknown) step positions and the vector of
(unknown) heights of the step function, ® is both the (unknown) upper end point
of the piecewise constant density and the threshold of the GPD, and ¾ and » are
respectively the scale parameter and shape parameter of the GPD.
Note that, following Conigliani and Tancredi (2005a), we assume that the pa-




varies with the treatment group i, and
6that » < 1, so that the expected mean cost for treatment i is ﬁnite and can be
written as













Moreover, in order to explore the use of truncated distributions for costs, as ad-
vocated by Thompson and Nixon (2005), here we consider the constraint » > ¡1;
recall that the GPD density has an upper bound of ® ¡ ¾=» on cij if » 2 (¡1;0),
while it has no upper limit if » ¸ 0.
Finally note that Bayesian inference for this model is possible using MCMC
methods. Details of the algorithm can be found in Tancredi et al. (2002), while
details about the prior distribution for the parameters can be found in Conigliani
and Tancredi (2005a).
3 A simulation experiment
Before moving to cost-eﬀectiveness analyses, we apply the two approaches presented
in Section 2 to the simple problem of computing a 95% posterior credible interval
for a mean cost, in order to compare their relative performance.
Thus, we generated 1000 samples of cost data and computed the credible intervals
assuming either the model averaging procedure of Section 2.1 or the semi-parametric
approach of Section 2.2. Under BMA we assumed prior model probabilities equal
to zero for the Weibull and the log-logistic, and to 1/3 for the remaining models.
Moreover, we completed the prior distributions for the parameters by letting ¹0
i =
1000, ¿0
i = 500, ¸0
i = 3 and º0
i = 3, so that the prior mean of ¹i and ¿i were 1000
and 1 respectively, and the 90% of the prior distribution for ¿i was between 0.25 and
2. Finally, under the mixture model we assumed non-informative priors for most
parameters, including » (Conigliani and Tancredi, 2005a). The results, presented
in Table 2 and Table 3 in terms of coverage and average size of the intervals, are
compared also with those obtained with the single parametric models considered
by BMA, i.e. the log-normal, the gamma and the GPD. We also computed the
proportion of the times that each of these distributions was the preferred model (for
having the highest posterior probability); these are the numbers in parentheses in
Table 2 and 3.
As data generating processes we considered a log-normal distribution with ¹ =
1000 and ¿ = 2, a Weibull distribution with ¹ = 1000 and ¿ = 1:5, a mixture
7of a gamma distribution and a GPD, both with ¹ = 1000 and ¿ = 2, and with
weights 1=8 and 7=8 respectively, and a mixture of three log-normal distributions
with ¹ = 1000, ¿ = 0:5;2;4 and weights 0.61, 0.20, 0.19 respectively. The resulting
distributions are plausible representations of cost data. In particular, the log-normal
experiment is an example of the diﬀerent performance of the two approaches when
the set of models M speciﬁed for BMA includes the distribution that generated the
data. Instead, in the remaining experiments none of the parametric models in M is
right, and the BMA results are determined by all the models that have a non-zero
posterior probability.
Samples of three diﬀerent sizes (n = 50;200;500) were drawn from each distribu-
tion; this represented a total of 12 diﬀerent simulation experiments. However we did
not apply the mixture model (1) when n = 50, since we felt there were not enough
observations to estimate its parameters. In fact, in the applications of extreme value
theory it is common practice to use between the 5% and the 10% of the sample to
estimate the upper tail of the model.
One point raises clearly from the results of Table 2 and Table 3, i.e. the pos-
terior credible intervals obtained with the mixture model (1) are wider than the
Table 2: A simulation experiment: coverage of the posterior credible intervals (in
parentheses the proportion of the times that each single parametric model was the
preferred one)
Generating n Log-normal Gamma GPD BMA Mixture
process
Log-normal 50 0.95 (0.660) 0.81 (0.008) 0.92 (0.332) 0.94 -
200 0.95 (0.945) 0.75 (0.000) 0.92 (0.055) 0.95 0.94
500 0.95 (0.998) 0.77 (0.000) 0.94 (0.002) 0.94 0.95
Weibull 50 0.93 (0.023) 0.92 (0.725) 0.92 (0.262) 0.93 -
200 0.21 (0.001) 0.93 (0.914) 0.94 (0.085) 0.94 0.96
500 0.01 (0.001) 0.91 (0.965) 0.95 (0.034) 0.92 0.95
Γ -GPD 50 0.84 (0.019) 0.88 (0.703) 0.91 (0.278) 0.92 -
mixture 200 0.09 (0.000) 0.86 (0.676) 0.93 (0.324) 0.90 0.95
500 0.00 (0.000) 0.85 (0.710) 0.95 (0.290) 0.90 0.95
Log-normal 50 0.94 (0.117) 0.86 (0.387) 0.93 (0.496) 0.89 -
mixture 200 0.76 (0.034) 0.77 (0.529) 0.89 (0.437) 0.85 0.93
500 0.39 (0.006) 0.75 (0.453) 0.89 (0.541) 0.85 0.94
8Table 3: A simulation experiment: average size of the posterior credible intervals
(in parentheses the proportion of the times that each single parametric model was
the preferred one)
Generating n Log-normal Gamma GPD BMA Mixture
process
Log-normal 50 889 (0.660) 643 (0.008) 696 (0.332) 801 -
200 465 (0.945) 322 (0.000) 379 (0.055) 459 1841
500 297 (0.998) 203 (0.000) 259 (0.002) 297 561
Weibull 50 1401 (0.023) 757 (0.725) 722 (0.262) 782 -
200 1049 (0.001) 373 (0.914) 392 (0.085) 380 786
500 823 (0.001) 234 (0.965) 265 (0.034) 238 371
Γ -GPD 50 1657 (0.019) 778 (0.703) 697 (0.278) 791 -
mixture 200 1388 (0.000) 375 (0.676) 382 (0.324) 379 1134
500 1210 (0.000) 234 (0.710) 261 (0.290) 242 449
Log-normal 50 877 (0.117) 508 (0.387) 595 (0.496) 569 -
mixture 200 459 (0.034) 260 (0.529) 308 (0.437) 290 2174
500 288 (0.006) 164 (0.453) 192 (0.541) 181 1227
corresponding ones obtained with Bayesian model averaging, but they are generally
better in terms of coverage. This is not surprising, and is related to the way the two
methods deal with model uncertainty. In fact, while the semi-parametric approach
of Section 2.2 does not require any assumption about the distribution of costs, and
allows inference on the mean cost to take account of the uncertainty about the tail,
BMA implies the speciﬁcation of a set of plausible models, which reduce the model
uncertainty. It follows that BMA will generally lead to smaller intervals, but the
characteristics of these intervals signiﬁcantly depends on which models were included
in M. In fact, the results of BMA are strongly related to those obtained with the
single models which have a non-zero posterior probability, which are not necessar-
ily models that ﬁt the data well. It follows that if we can specify a set of models
that include the one that generated the data or at least a good approximation of
it, as it is the case for instance for the log-normal data, BMA will provide more
precise inference on mean cost than the mixture model. Otherwise we expect the
mixture model to perform better. And in fact when the data are generated from
the gamma-GPD mixture or the mixture of log-normal distributions, the coverage
of the intervals produced with the semi-parametric approach is signiﬁcantly better
9Table 4: Low back pain trial: sample descriptive statistics of X-ray costs and rMRI
costs
X ray rMRI
sample size 166 162
mean 1515 2187












than the one obtained with BMA. And if n is large enough (for instance n = 500),
at least for the gamma-GPD mixture, also the diﬀerence in terms of average size of
the intervals produced by the two approaches is less notable.
Finally note that the results of Table 2 and Table 3 conﬁrm the ﬁnding of Briggs
et al. (2005) that inferences based on the incorrect assumption of lognormality
perform very poorly: in particular for the larger datasets, the coverage of the in-
tervals obtained with the log-normal distribution when the true distribution is not
log-normal are disastrous. In this sense, it is interesting to see the paper by Royall
and Tsou (2003), where it is shown that while if we assume for instance a Gamma
distribution the object of inference continues to be the mean of the true generating
process also when the model fails, if we assume the log-normal working model then
what the likelihood represents evidence about when the model fails is not Ef(c) but
the quantity exp(Ef(log(c)) + 1
2varf(log(c))).
4 Analysis of the Low Back Pain Trial data
We present an example using a study on low back pain (Jarvik et al., 2003). A total
of 380 patients (out of which 328 were included in the health economic evaluation)
were randomised in a 1:1 ratio to investigation by standard X-ray investigation
and rapid magnetic resonance imaging (rMRI), and were followed for 12 months.
Aim of the trial was to investigate whether rMRI would allow better diagnosis and
treatment, or lead to unnecessary treatment without improvement in symptoms.
The primary clinical endpoint was the change from baseline of the modiﬁed Roland
10back pain score (Patrick et al., 1995), while the primary economic endpoint was the
total health care cost (in US$). This dataset has been analyzed by Thompson and
Nixon (2005) in order to illustrate how sensitive inference about cost-eﬀectiveness
is to the choice of the model for costs.
The data are shown in Figure 1. Under both treatments the eﬀects are appar-
ently well represented by a normal distribution, while the distribution of costs is
clearly highly skew and heavy-tailed; this fact is conﬁrmed also by the sample sum-
maries shown in Table 4. In particular, for both treatment groups the standard
deviations are large, indicating that the data are spread quite far around the mean,
and the median cost is smaller than the mean, indicating positively skew data; this
fact is conﬁrmed also by the standard skewness statistic ¹3=¾3. Finally, the kur-
tosis statistic ¹4=¾4 indicates that the two distribution of costs are signiﬁcantly
leptokurtic.
We now apply the approaches of Section 2.1 and Section 2.2 to this data set,
and compare the results also with those that we obtain if we assume the single
parametric models included in M. Under BMA we assume that the prior model









































































































































1Table 5: Low back pain trial: posterior summaries of mean costs
Model E(¹1) PCI0:95 ¼1 (mjD) E(¹2) PCI0:95 ¼2 (mjD)
Mixture 1555 1301;1837 - 2377 1840;3051 -
BMA 1542 1283;1885 - 2047 1628;2594 -
Log-normal 1852 1402;2476 0.01 2051 1630;2592 0.99
Gamma 1511 1275;1785 0.49 2102 1784;2479 0
GPD 1565 1285;1930 0.50 2076 1677;2580 0.01
remaining models. Moreover, the prior distributions for the unknown parameters
are completed by letting ¹0
i = 1000, ¿0
i = 500, ¸0
i = 3 and º0
i = 3. Under the mixture
model we assume non-informative priors for most parameters, while we model the








" » N (0;1)
where " is estimated using data from both treatment groups; note that this prior
reﬂects the prior belief that the tails of the distributions of costs are not very diﬀerent
between the two treatments (Conigliani and Tancredi, 2005a; O’Hagan and Stevens,
2003). For the eﬀects we suppose that







where the conditional mean °ij depends linearly on the cost cij of patient j under
treatment i :
°ij = ¯i + ±icij:
The overall mean eﬀect in the i-th arm of the trial can then be written as
°i = ¯i + ±i¹i:
Table 5 shows a 95% posterior credible interval (PCI0:95) and a point estimate
for the mean costs ¹1 and ¹2 obtained with the diﬀerent models assumed for costs,
and it is interesting to note how these results are slightly diﬀerent from those of
Section 3. In fact, while for the rMRI group the posterior credible interval obtained
with the mixture model (1) is wider than the one obtained with BMA (although
12the diﬀerence in width is not as signiﬁcant as in Section 3), and the estimated mean
cost obtained with the mixture model is higher than the one obtained with BMA,
for the X-ray group the approaches of Section 2.1 and of Section 2.2 produce very
similar results.
Within the BMA approach it is also interesting to look at the posterior model
probabilities ¼i (mjD) for the log-normal, the gamma and the GPD distributions,
that are also presented in Table 5 for each arm of the trial. In particular, while
for the rMRI group the data deﬁnitely support the log-normal distribution, for the
X-ray group both the gamma and the GPD are plausible models, with posterior
probabilities 0.49 and 0.50 respectively. Note that this is exactly a situation where
it is appropriate to apply model averaging: instead of choosing between the gamma
and the GPD, and then studying the sensitivity of the conclusions in terms of cost-
eﬀectiveness, model averaging takes into account both models.
Finally, in order to interpret the results of the mixture model, it is interesting
to look at the posterior distributions of its parameters. In particular, Figure 2 show
the posterior distribution of the shape parameter », the threshold ® and the number
of steps s for the two treatment groups. Note that even with such small data set
and with mostly non-informative priors, these posterior distributions are quite con-
centrated, so that they give clear indications for the estimation of these parameters.
Moreover, it is interesting to notice that the two posterior distributions of s are
concentrated on the value 3 (the posterior means are 3.44 and 3.05 respectively), so
that the evidence is that only 3 steps are suﬃcient to model adequately the bulk of
the data. Finally, it is worth noting that the posterior mean of » and the posterior
probability that » < 0 are -0.05 and 0.70 respectively for the X-ray group, and -0.70
and 0.99 respectively for the rMRI group. It follows that for both treatment groups











48851 i = 1
23257 i = 2:
In order to assess if rMRI is more cost-eﬀective than standard X-ray, we now look
at the joint posterior distribution of the cost diﬀerential ∆c and the eﬀect diﬀerential
∆e. These are summarised as 95% contour plots in Figure 3 (obtained assuming the
normality of the bivariate posterior distribution), while the corresponding posterior
summaries and the corresponding cost-eﬀectiveness acceptability curves are shown
13in Table 6 and in Figure 4 respectively.
Several points emerge from these results. First, the estimated eﬀect diﬀerence is
quite close to zero, so that rMRI does not seem to allow better diagnosis and treat-
ment. Only if we assume a log-normal distribution in the X-ray group the probability
that ∆e is greater than zero reaches 0.23, but this model is not supported by the
data, and therefore the corresponding results should not be considered. Second,
there is evidence of a higher mean cost in the rMRI group under all the models
assumed for costs, and in particular under the mixture model, with an estimated
mean cost diﬀerence of $822, compared to the $505 obtained with BMA (again, only
if we assume a log-normal distribution in the X-ray group the estimated mean cost
diﬀerence does not go above $250, but this model is not supported by the data and
therefore these results are of no interest). The discrepancy between the results of
the approaches of Section 2.1 and Section 2.2 can be seen also when comparing the







































































































































































































































































4Table 6: Low back pain trial: posterior summaries of cost diﬀerential and eﬀect
diﬀerential
X-ray rMRI E(∆c) PCI0:95 P(∆c> 0) E(∆e) PCI0:95 P(∆e> 0)
Mixture Mixture 822 212;1538 1 0.03 -1.4;1.5 0.51
BMA BMA 505 ¡36;1116 0.97 0.07 -1.4;1.5 0.54
logN logN 199 ¡554;902 0.72 0.24 -1.2;1.7 0.62
logN Gamma 250 ¡449;842 0.79 0.23 -1.2;1.7 0.62
logN GPD 224 ¡512;911 0.75 0.24 -1.2;1.7 0.62
Gamma logN 540 30;1133 0.98 0.05 -1.4;1.5 0.53
Gamma Gamma 591 176;1030 1 0.04 -1.4;1.5 0.52
Gamma GPD 565 79;1123 0.99 0.05 -1.4;1.5 0.53
GPD logN 486 ¡72;1092 0.95 0.08 -1.3;1.5 0.54
GPD Gamma 537 41;1011 0.98 0.07 -1.4;1.5 0.54
GPD GPD 511 ¡35;1094 0.97 0.08 -1.3;1.5 0.54
contour plots in Figure 3, where the diﬀerence in the shape of the two joint dis-
tributions with respect to the vertical scale is quite obvious, and by looking at the
CEACs in Figure 4. In fact, although the two curves have very similar behaviours,
if we look at the values of K where the probability that rMRI is cost-eﬀective is
at least 0.5, we ﬁnd K ¸ $7400 under BMA, and K ¸ $30000 under the mixture
model. It follows that in terms of cost-eﬀectiveness, here the semi-parametric ap-
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Figure 3: Low back pain trial: contour plots of cost-eﬀectiveness density
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Figure 4: Low back pain trial: cost-eﬀectiveness acceptability curves
proach and the Bayesian model averaging applied to the lognormal, gamma and
GPD, produce rather diﬀerent results. Note that from Table 5 we know that this
is due to the fact that in the rMRI group the mixture model gives more weight to
the upper tail of the cost distributions than any of the models included in M, and
in this sense it is particularly interesting to explore the behaviour of BMA when
widening M. If for instance we include also the Weibull and the log-logistic distri-
butions in M, plausible models for the X-ray group become the gamma, the GPD
and the Weibull, with posterior probabilities 0.22, 0.23 and 0.55 respectively, but
for the rMRI group the data still only support the log-normal distribution, so that
in terms of cost-eﬀectiveness the two analyses with BMA are quite similar, as it is
shown by the contour plots and the CEACs in Figure 5.
5 Discussion
Most of the recent literature on cost-eﬀectiveness analyses of clinical trial data agrees
that inferences are signiﬁcally sensitive to the choice of the model for costs, and in
particular to how the upper tail of the cost distribution beyond the observed data
is modelled. In particular it often happens that parametric models that ﬁt the data
equally well produce very diﬀerent answers; conversely, models that ﬁt badly can
give similar inferences to those that ﬁt well.



































































Figure 5: Low back pain trial: cost eﬀectiveness analysis including the Weibull and
the log-logistic distributions in the BMA procedure (in parentheses the number of
models included in M)
In this paper we have considered two diﬀerent approaches to overcome this prob-
lem. The ﬁrst one combines the semi-parametric approach to density estimation
based on mixture models and the semi-parametric approach to tail estimation based
on extreme value theory. The result is a very ﬂexible model able to ﬁt data set with
very diﬀerent shapes both in the bulk of data and in the tail. One drawback of
this approach is that there is a price to pay for so much ﬂexibility in terms of pre-
cision and eﬃciency of the corresponding inferences. Another problem is that for
estimating the parameters of the the mixture model, and in particular the param-
eters of the tail, we need a large number of observations in each arm of the trial.
The second approach is based on Bayesian model averaging performed on a sensible
set of models for cost data, and is somehow in the spirit of the sensitivity analyses
advocated by Thompson and Nixon (2005). It requires the speciﬁcation of a set M
of plausible models, but instead of studying how the conclusions change with the
diﬀerent models, it takes into account the inferences obtained with all the models
in M that have a non-zero posterior probability. One drawback of this approach
is that the models with a non-zero posterior probability are not necessarily models
that ﬁt the data well. It follows that particular care should be devoted to specify M,
in the sense that it should include all parametric models that might have generated
17cost data. On the other hand, it is worth pointing out that the wider is M, the
more is diﬃcult to assign and interpret the prior model probabilities. In fact, there
is no requirement for the models in M to be distinct, so that for instance in our
examples the exponential distribution belongs to the Weibull, the gamma and the
GPD families. And in such cases, as pointed out for instance in O’Hagan and Foster
(2004), a prior model probability may not reﬂect the total probability assigned to
that model as a set of data-generating processes.
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